A new force in the European chemical and pharmaceutical engineering sector: TTP AG is now also acquiring the French subsidiary of NNE A/S

Frankfurt am Main/Copenhagen (ots) - TTP AG, Frankfurt/Main and
its subsidiary TTP France S.A.S. are now also acquiring NNE S.A.S.,
the French engineering arm of the Danish company NNE A/S with 87
employees at the pharmaceutical industry sites in Paris, Lyon and
Chartres.

Three weeks ago, TTP AG and NNE A/S announced the takeover of
NNE's companies in Germany, Switzerland and Belgium by TTP AG. The
NNE companies are specialised in engineering and consulting services,
particularly for major projects in the growth markets of
biotechnology and pharmaceuticals. TTP AG plans to manage the
acquired European NNE companies under the PHARMAPLAN name. The French
company was also known as NNE PHARMAPLAN until 2017. In 2018, the NNE
companies in Germany, France, Switzerland and Belgium had a total
turnover of approximately EUR75 million and employed around 440
people.

TTP AG is the majority shareholder of TRIPLAN AG, based in Bad
Soden am Taunus, an engineering service company with a focus on the
life science, chemical and petrochemical sectors. TRIPLAN and
PHARMAPLAN are to complement each other in the future under the
umbrella of TTP AG to form a comprehensive service portfolio for the
process industry.

NNE France was founded in 2004 by NNE A/S, a wholly owned
subsidiary of the international pharmaceutical group Novo Nordisk
A/S. The local French production site of Novo Nordisk A/S, has been a
key business area and is expected to continue under the new ownership
of TTP S.A.S. Under the umbrella of TTP AG and in combination with
TRIPLAN AG, the French company will achieve greater independence and
open up its expertise to the entire market in the future.

Joachim Grendel, CEO of TTP AG: "NNE France will be operating
independently under the name PHARMAPLAN in the future and can thus
take advantage of new market opportunities in the pharmaceutical
industry. At the same time, we will be able to present the entire
service portfolio of TRIPLAN and PHARMAPLAN in France in the future.
This complementary combination provides a comprehensive engineering
offer for EPCM projects in the fields of pharmaceuticals,
biotechnology and life science, but also in the chemical and refinery
segments."

Dr Andreas Bonhoff, CFO of TRIPLAN AG: "We are delighted with the
confidence placed in us by the employee representatives of the French
NNE company. Together we are convinced we can develop attractive
future prospects for the company's employees. The transaction will
strengthen the independence of the French sites and make them part of
a leading European engineering service provider."

Jesper Kløve, CEO of NNE A/S: "It is a great pleasure to hand over
the NNE France company to the TTP AG Group, as it both creates a
strong foundation for growing the local business in France and
enforces the strategic journey of all European NNE companies
acquired. I have great confidence that TTP AG Group will create a
bright future for each and every one of the acquired companies."

The acquisition is expected to take effect at the end of March
2019. The parties have agreed not to disclose the purchase price.

About TTP AG

TTP AG in Frankfurt/Main is specialised in production-related
engineering services for the process industry. It is the majority
shareholder of TRIPLAN AG, based in Bad Soden am Taunus, an
engineering service company with a focus on the life science,
chemical and petrochemical sectors.

About TRIPLAN AG

TRIPLAN AG and its affiliated companies ("TRIPLAN" or the "TRIPLAN
Group") provide engineering services for plant construction in the
chemical, pharmaceutical and petrochemical industries. The range of
services includes technical consulting, plant planning in close
alignment with operations, as well as the overall planning of new and
existing laboratory, pilot, production, infrastructure and supply
plants.

As an independent and neutral general and component planner,
TRIPLAN undertakes the technical development for new construction
projects, conversion projects and the modernisation and optimisation
of industrial plants. It has a renowned and long-term customer base
of companies in the regional environments of its individual
locations. Multi-year framework agreements have been concluded with
many of these customers. TRIPLAN AG is active in Germany, Switzerland
and India and employs 420 people with a consolidated annual turnover
of EUR47 million in 2018.

About NNE A/S

NNE A/S (NNE) is a leading international company specialised in
pharmaceutical engineering. NNE helps pharmaceutical companies to
bring products to market and solves its customers' most complex
manufacturing challenges in the areas of biotech/API, oral solid
dosage, fill and finish, and assembly and packaging.

The company provides expert pharmaceutical engineering throughout
the entire manufacturing and project life cycle from front-end
studies, design and project execution to optimisation of running
operations. NNE's primary areas of expertise are pharmaceutical
processes, facilities and automation within GMP-regulated
environments. NNE is a recognised contributor to many of the
organisations that set standards in pharmaceutical quality,
manufacturing/engineering and guidelines. NNE has a strong customer
base developed over many years with a high degree of repeat business
year after year.

Contact:
B.L.B.R
Burkhard Leschke
Brand Relations GmbH
Eigelstein 103-113
50668 Cologne, Germany
Phone +49-221/27190656
Mobile +49-1609-380-3331
b.leschke@blbr.de

Original-Content von: TTP AG / TRIPLAN AG / NNE A/S, übermittelt durch news aktuell